The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility.
Apoptosis
Biomarkers, Tumor
/ genetics
Cell Movement
Cell Proliferation
Colonic Neoplasms
/ genetics
F-Box Proteins
/ genetics
Focal Adhesion Kinase 2
/ genetics
Gene Expression Regulation, Neoplastic
Humans
Jumonji Domain-Containing Histone Demethylases
/ genetics
Male
Phosphatidylinositol 3-Kinases
/ genetics
Prostatic Neoplasms
/ genetics
Tumor Cells, Cultured
FAK
KDM2B
PI3K
migration
prostate cancer
Journal
Cancer biology & therapy
ISSN: 1555-8576
Titre abrégé: Cancer Biol Ther
Pays: United States
ID NLM: 101137842
Informations de publication
Date de publication:
02 06 2020
02 06 2020
Historique:
pubmed:
17
3
2020
medline:
6
7
2021
entrez:
17
3
2020
Statut:
ppublish
Résumé
Recent studies revealed that the histone demethylase KDM2B regulates the epithelial markers E-Cadherin and ZO-1, the RhoA/B/C-small-GTPases and actin cytoskeleton organization, in DU-145 prostate- and HCT-116 colon-tumor cells. Here we addressed the role of KDM2B in the activation of Focal Adhesion Kinase (FAK)-signaling and its involvement in regulating tumor cell motility. We used RT-PCR for gene transcriptional analysis, Western blotting for the assessment of protein expression and activity and wound-healing assay for the study of cell migration. KDM2B overexpression or silencing controls the activity of FAK in DU-145 prostate- and HCT-116 colon-tumor cells without affecting gene transcription and protein expression of this kinase. Upon KDM2B overexpression in DU-145 cells, significantly enhanced migration was observed, which was abolished in cells pretreated by the specific phosphoinositide-3 kinase (PI3 K) inhibitor LY294002, implying involvement of FAK/PI3 K signaling in the migration process. In line with this, the p85-PI3 K-subunit was downregulated upon knockdown of KDM2B in DU-145 cells, while the opposite effect became evident in KDM2B-overexpressing cells. These results revealed a novel functional role of KDM2B in regulating the activation of the FAK/PI3 K signaling in prostate cancer cells that participates in the control of cell motility.
Identifiants
pubmed: 32175798
doi: 10.1080/15384047.2020.1736481
pmc: PMC7515453
doi:
Substances chimiques
Biomarkers, Tumor
0
F-Box Proteins
0
Jumonji Domain-Containing Histone Demethylases
EC 1.14.11.-
KDM2A protein, human
EC 1.14.11.27
Focal Adhesion Kinase 2
EC 2.7.10.2
PTK2B protein, human
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
533-540Références
Pharmacol Ther. 2015 Feb;146:132-49
pubmed: 25316657
Arch Biochem Biophys. 2018 Jul 15;650:59-74
pubmed: 29753725
Expert Opin Ther Targets. 2013 Aug;17(8):951-63
pubmed: 23746222
Cell Physiol Biochem. 2007;20(6):977-86
pubmed: 17982280
Expert Opin Investig Drugs. 2010 Jun;19(6):777-88
pubmed: 20465362
Mol Med. 2011 Jan-Feb;17(1-2):48-58
pubmed: 20957335
Oncogene. 2000 Nov 20;19(49):5606-13
pubmed: 11114741
Cell Physiol Biochem. 2016;38(1):94-109
pubmed: 26741994
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2641-6
pubmed: 19202064
J Biol Chem. 1996 Oct 18;271(42):26329-34
pubmed: 8824286
J Biol Chem. 2011 Sep 23;286(38):33061-9
pubmed: 21757686
Cell Physiol Biochem. 2014;34(4):1402-12
pubmed: 25301365
Nat Struct Mol Biol. 2008 Nov;15(11):1169-75
pubmed: 18836456
Cancer Biol Ther. 2015;16(1):52-9
pubmed: 25427201
Cell Signal. 2017 Aug;36:222-229
pubmed: 28506929
Cytoskeleton (Hoboken). 2014 May;71(5):285-93
pubmed: 24616288
Annu Rev Cell Dev Biol. 2017 Oct 6;33:103-125
pubmed: 28793794
Mol Endocrinol. 2003 May;17(5):870-81
pubmed: 12554777
Exp Cell Res. 2017 Sep 1;358(1):78-85
pubmed: 28412244
Cell Signal. 2013 Jan;25(1):66-73
pubmed: 23316499
Cell Biochem Funct. 1994 Dec;12(4):267-74
pubmed: 7834816
Mol Hum Reprod. 2014 Feb;20(2):139-47
pubmed: 24043696
Blood. 2011 Apr 7;117(14):3869-80
pubmed: 21310926
Adv Cancer Res. 2009;102:103-69
pubmed: 19595308
J Cell Biochem. 1997 Jun 15;65(4):492-500
pubmed: 9178099
Biochem Biophys Res Commun. 1996 Jul 5;224(1):23-6
pubmed: 8694818
Int J Mol Sci. 2017 Jan 05;18(1):
pubmed: 28067792
Mol Cell. 2011 Jul 22;43(2):285-98
pubmed: 21777817
FEBS J. 2008 Aug;275(16):4074-87
pubmed: 18631173
Semin Cancer Biol. 2008 Feb;18(1):12-22
pubmed: 17928234
Cell Commun Signal. 2015 Jan 29;13:6
pubmed: 25630770
Sci Rep. 2016 Jan 14;6:19276
pubmed: 26763945
Adv Drug Deliv Rev. 2011 Jul 18;63(8):610-5
pubmed: 21118706
Biochim Biophys Acta Mol Cell Res. 2018 Apr;1865(4):587-597
pubmed: 29408056
Onco Targets Ther. 2017 Jun 26;10:3131-3144
pubmed: 28706445
J Pharmacol Exp Ther. 2011 Nov;339(2):403-11
pubmed: 21828260
Cancer Lett. 2016 Oct 1;380(2):505-512
pubmed: 27452906
Small GTPases. 2016 Oct;7(4):207-221
pubmed: 27628050
Cell Mol Life Sci. 2018 Jun;75(12):2111-2124
pubmed: 29500478
Oncogene. 2017 Jan 5;36(1):71-83
pubmed: 27212030
FEBS Lett. 2008 Jun 18;582(14):2120-7
pubmed: 18325339
FEBS Lett. 2016 Mar;590(6):705-15
pubmed: 26878191
Dev Cell. 2009 Sep;17(3):310-22
pubmed: 19758556
Cancer Res. 2014 Jul 15;74(14):3935-46
pubmed: 24853546
Cell Physiol Biochem. 2018;47(1):368-377
pubmed: 29772566
J Cell Biol. 2018 Feb 5;217(2):447-457
pubmed: 29233866
Expert Opin Ther Targets. 2010 Jan;14(1):77-94
pubmed: 20001212
Oncotarget. 2014 Jul 15;5(13):4799-810
pubmed: 25015419
Oncogene. 2018 Mar;37(12):1654-1668
pubmed: 29335520
Breast Cancer Res. 2016 Aug 05;18(1):81
pubmed: 27495308